What are the odds of dying from prostate cancer?
Evidence quality 4.75/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 4/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 5/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, subgroup
1 in 50
2.0% lifetime chance
Most people overestimate this.
range 1 in 83 to 1 in 36
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Prostate cancer sits in a strange place in the public mind. Most men have heard the "1 in 8" diagnosis figure — roughly the same headline number that attaches to female breast cancer — and most file it as a major threat on that basis. What the typical reader does not internalise is that prostate cancer has the largest gap between *incidence* and *mortality* of any common cancer: the great majority of men diagnosed with it do not die of it, and a meaningful share of older men carry histologically detectable prostate cancer that never causes symptoms at all. The screening literature has been openly arguing about this gap for over a decade, and the USPSTF has moved the recommendation twice in response. Public intuition has not caught up to that debate.
Rough estimate: 50% of US adults are very or somewhat worried about getting cancer (Gallup, all sites); most men conflate the 1-in-8 diagnosis figure with the much lower death rate
Source: Gallup (2021) — Cancer, Heart Disease Worries Eclipse COVID-19
Actual
~397,000 prostate cancer deaths per year globally (men)
global men, all ages
Show derivation
WCRF / IARC GLOBOCAN 2022 reports ~1.47 million new prostate cancer cases and ~397,430 deaths per year globally, making it the 4th most common cancer overall and the 2nd most common cancer in men. Women are not at risk (prostate is a male-only organ), so the population at risk is global adult men, roughly 3 billion. ~397,000 deaths per year across ~3 billion adult men is ~1.3 per 10,000 men per year on a flat-hazard basis, which compounds naively to ~0.8% over 60 adult years. That is a floor rather than a ceiling because prostate cancer mortality is heavily concentrated above age 70 — the SEER median age at prostate cancer death is 79 — so age-weighting pulls the realistic lifetime number higher, into the 1.5-2.5% range for a generic adult man alive today. The American Cancer Society’s direct US figure is 1 in 44 (~2.3%), and the SEER lifetime diagnosis figure is ~12.9% (roughly 1 in 8), with a long-run case fatality well under 20% driven by 5-year relative survival of 97.9%. Headline figure 0.02 (~1 in 50) for the global adult men baseline, bracketed by the direct US figure on the high side and by lower- incidence regions (notably East Asia) on the low side. Women are excluded from the headline because the risk is zero by anatomy; scope is global-adult- lifetime to match the cancer-lifetime sibling entries with the male-only population at risk flagged in the body text and regional breakdown.
Caveats: This entry is lifetime *mortality* from prostate cancer, not incidence. The wide…
This entry is lifetime *mortality* from prostate cancer, not incidence. The widely quoted "1 in 8" figure is the lifetime probability a US man will be *diagnosed* with prostate cancer; the lifetime probability he will *die* of it is about 1 in 44 per ACS — roughly 5.5x smaller. The diagnosis/death gap is larger for prostate cancer than for any other common cancer on this site. Five-year relative survival is 97.9% per SEER, higher than for any other common cancer, and a meaningful share of older men carry histologically detectable prostate cancer that never causes symptoms: autopsy studies have found microscopic prostate cancer in a majority of men over 70 who died of unrelated causes. This is the main reason USPSTF recommendations on PSA screening have moved twice in the past fifteen years and still describe the decision as individual rather than routine — overdiagnosis and overtreatment are the dominant harms, and the mortality benefit, while real, is modest and context-dependent. Prostate cancer is also a male-only disease by anatomy, so the "global adult" framing of the headline number is population-weighted across the roughly half of adults at risk. For women the probability is zero; for men the population-average figure near 1 in 50 lifetime hides an enormous gap between indolent low-grade disease (where many men die *with* prostate cancer, not *of* it) and aggressive high-grade disease (where the 5-year survival drops sharply). The Black-White mortality gap is the largest demographic disparity for any common cancer in the US and is partly biological and partly structural — current evidence does not let the two contributions be cleanly separated.
Regional breakdown
The headline figure averages across very different populations. Here’s how the probability varies by geography or context:
| Region / context | Lifetime probability | Notes |
|---|---|---|
| Global average (men) | 1 in 50 |
~397K deaths/yr across ~3B adult men (WCRF / IARC GLOBOCAN 2022); age-weighted global adult lifetime figure |
| US men | 1 in 43 |
ACS direct SEER-based estimate: ~1 in 44 lifetime death alongside ~1 in 8 lifetime diagnosis |
| African American men | 1 in 25 |
~2x higher mortality than white Americans per Siegel et al. 2024 in CA: A Cancer Journal for Clinicians; partly biology (higher incidence and more aggressive disease), partly differential access to timely screening and treatment |
| East Asia (men) | 1 in 200 |
Age-standardized prostate cancer mortality is an order of magnitude lower in East Asian populations than in men of European or African descent; the gap partly survives migration, suggesting a real genetic component alongside diet and screening differences |
| Women (all regions) | — |
Not anatomically possible; women do not have a prostate gland |
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Charred meat & cancer
How much does eating charred or well-done grilled meat actually raise your cancer risk?
Low-fiber CRC risk
What are the odds of getting colorectal cancer from not eating enough fiber?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
Prostate cancer kills about 397,000 men a year worldwide per the IARC’s GLOBOCAN 2022 totals (as republished by the World Cancer Research Fund), against roughly 1.47 million new cases — the 4th most common cancer globally and the 2nd most common in men. Age-weighted across a global adult-male population, that works out to a lifetime mortality figure near 1 in 50 for a generic man alive today. The American Cancer Society’s direct US figure is slightly higher, at 1 in 44 (about 2.3%). In the Likelier catalogue prostate cancer lands in roughly the same order of magnitude as colorectal, breast, and lung cancer deaths — mid-pack among cancers, well below cardiovascular disease, and several orders of magnitude above almost every non-disease entry on this site.
What makes prostate cancer unusual is the gap between those two numbers. The ACS also reports that about 1 in 8 US men will be diagnosed with prostate cancer in their lifetime, and SEER puts the 5-year relative survival at 97.9% — higher than for any other common cancer. A roughly 5.5x gap between diagnosis and death is the largest of any common cancer on this site, and it reflects something specific about the biology: a large share of prostate cancers are indolent, slow-growing, and clinically inconsequential. Autopsy studies have repeatedly found microscopic prostate cancer in a majority of men over 70 who died of unrelated causes. The blunt summary is that many men die with prostate cancer, not of it — and much of the “1 in 8” headline is disease that would never have killed anyone if it had not been found.
This is why PSA screening has been openly contested for the better part of two decades. The US Preventive Services Task Force gave prostate cancer screening a blanket Grade D (“recommend against”) in 2012, then upgraded to Grade C (“individual decision”) for men aged 55-69 in 2018 after longer follow-up from the European ERSPC trial showed a real but modest mortality benefit — roughly 1.3 prostate cancer deaths prevented per 1,000 men screened over 13 years. Against that, USPSTF estimates that 20-50% of screen-detected prostate cancers may be overdiagnosed, and treatment carries non-trivial rates of incontinence and erectile dysfunction. Screening remains Grade D for men 70+. The Likelier tag here is overrated in a narrow sense: the headline incidence number massively overstates the death risk, and the public reflex to treat “1 in 8” as a mortality figure is the main thing the numbers argue against. The disease itself is a major cancer that absolutely kills people; it just kills far fewer of the men it is found in than the diagnosis rate would suggest.
Where the headline does not apply: the demographic spread is wider than for most cancers on this site. Age dominates — SEER’s median age at prostate cancer death is 79, roughly 6 in 10 diagnoses occur at 65 or older, and the disease is rare before 40. Race matters more than for almost any other common cancer: Siegel and colleagues’ 2024 paper in CA: A Cancer Journal for Clinicians reports that prostate cancer mortality is roughly twice as high in Black men as in White men in the US, the largest racial gap for any common cancer. The disparity is partly biology (higher incidence and more aggressive disease at diagnosis in men of African descent) and partly structural (differential access to timely screening and treatment), and current evidence does not cleanly separate the two. East Asian men sit at the other end: age- standardized prostate cancer mortality is roughly an order of magnitude lower in East Asia than in North America or Sub-Saharan Africa, and the gap partially survives migration, suggesting a genuine genetic component alongside diet and screening differences. And because prostate cancer is male-only by anatomy, the global-adult framing of the headline number is a population-weighted average across the half of adults at risk. For women the probability is zero; for men, the honest one-line summary is a diagnosis figure near 1 in 8, a death figure near 1 in 44 in the US and 1 in 50 globally, and the reminder that those two numbers are not the same number.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] World Cancer Research Fund International — Prostate cancer statistics
Prostate cancer statistics- Statistic
1,467,854 new prostate cancer cases and ~397,430 deaths globally in 2022; 4th most common cancer worldwide and 2nd most common cancer in men- Excerpt
“"There were 1,467,854 new cases of prostate cancer in 2022. [...] Prostate cancer is the 4th most common cancer worldwide. It is the 2nd most common cancer in men." ”
- Source data from
- 2024-05-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- WCRF republishes the IARC GLOBOCAN 2022 prostate cancer totals: ~1.47M new cases and ~397K deaths per year. Divided across ~3B adult men worldwide, that is ~1.3 per 10,000 per year on a flat-hazard basis. Age-weighting (prostate cancer mortality is concentrated above age 70, with a median age at death of 79 per SEER) pulls the realistic cumulative lifetime mortality near 1.5-2.5% globally. Used as the primary global headline and for the "4th most common / 2nd in men" framing in the body text. The ~3.7x ratio between global cases and deaths is the largest for any common cancer and is the central story of this entry.
- Independence
- WCRF’s cancer statistics pages are a downstream republication of IARC GLOBOCAN 2022. Treated as partially dependent with any other IARC-derived source; used here because the direct IARC news release for GLOBOCAN 2022 does not break out prostate cancer totals in its text.
-
[2] Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute — Cancer Stat Facts: Prostate Cancer
Cancer Stat Facts: Prostate Cancer- Statistic
~12.9% US lifetime risk of prostate cancer diagnosis; 5-year relative survival 97.9% (2015-2021); median age at death 79; ~313,780 new cases and ~35,770 deaths estimated for 2025; age-adjusted death rate declining ~0.6% per year- Excerpt
“"Approximately 12.9 percent of men will be diagnosed with prostate cancer at some point during their lifetime, based on 2018–2021 data, excluding 2020 due to COVID." ”
- Source data from
- 2025-04-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- SEER gives direct US lifetime incidence of ~12.9% (the "roughly 1 in 8" that most men have heard). With 5-year relative survival of 97.9% and a median age at death of 79, the implied long-run case fatality is small: ~12.9% incidence multiplied by a roughly 15-20% long-run case fatality gives a US lifetime prostate-cancer-death probability near 2.0-2.5%, consistent with ACS’s direct "1 in 44" figure. Anchors the US row in the regional breakdown and the top of the Likelier uncertainty band. The 97.9% 5-year survival is the mechanism that creates the diagnosis/ death gap flagged in the body text — it is higher than the figure for any other common cancer.
- Independence
- SEER (NCI) and IARC GLOBOCAN (WHO/WCRF) are methodologically independent compilation pipelines. SEER uses US vital registration and population- based cancer registries; IARC aggregates national registry data worldwide. The two are used here as independent anchors on the US and global ends of the regional breakdown.
-
[3] American Cancer Society — Key Statistics for Prostate Cancer
Key Statistics for Prostate Cancer- Statistic
About 1 in 8 US men will be diagnosed with prostate cancer during their lifetime; about 1 in 44 will die of it; ~333,830 new cases and ~36,320 deaths projected for 2026- Excerpt
“"About 1 in 8 men will be diagnosed with prostate cancer during their lifetime. [...] About 1 in 44 men will die of prostate cancer. [...] Prostate cancer risk is also higher in Black men in the US and the Caribbean. [...] About 6 in 10 prostate cancers are diagnosed in men who are 65 or older, and it is rare in men under 40." ”
- Source data from
- 2026-01-16
- Accessed
- 2026-04-11 · archived copy
- Calculation
- ACS gives both the 1-in-8 diagnosis and the 1-in-44 death figure explicitly. The 5.5x gap between the two is the load-bearing fact for this entry and the main calibration story: readers reliably quote "1 in 8" as if it were a death rate, when it is in fact the incidence rate — the death rate is ~2.3%, an order of magnitude below what the headline implies. The age-skew ("6 in 10 diagnoses at 65 or older") and the race-disparity framing are used to support the body text and the regional_breakdown / personal_factor_multipliers blocks.
- Independence
- ACS derives its US lifetime-probability figures from SEER incidence and mortality data. Treat these two as a single pipeline for US-specific numbers rather than as independent verification of each other.
-
[4] US Preventive Services Task Force — Final Recommendation Statement: Prostate Cancer: Screening
Final Recommendation Statement: Prostate Cancer: Screening- Statistic
USPSTF recommends individual decision-making on PSA screening for men 55-69 (Grade C, upgraded from D in 2012); recommends against PSA screening for men 70+ (Grade D); notes 20-50% of screen-detected cases may be overdiagnosed- Excerpt
“"The decision to undergo periodic prostate-specific antigen (PSA)-based screening for prostate cancer should be an individual one. [...] The USPSTF recommends against PSA-based screening for prostate cancer in men 70 years and older." ”
- Source data from
- 2018-05-08
- Accessed
- 2026-04-11 · archived copy
- Calculation
- USPSTF is the authoritative US primary-care screening guideline. The 2018 move from a blanket Grade D (recommend against) to Grade C (individual decision) for men 55-69 was a direct response to the longer-term ERSPC trial follow-up, which showed screening prevents about 1.3 prostate cancer deaths per 1,000 men screened over 13 years and reduces metastatic disease by about 3 per 1,000. That is a real but modest mortality benefit, set against a 20-50% overdiagnosis rate. Used here as the authoritative basis for the overdiagnosis framing in the body text and the myth_framing: overrated tag — "overrated" in the sense that the headline incidence figure massively overstates the death risk, not that the disease itself is not a major cancer.
- Independence
- USPSTF evidence synthesis is methodologically independent of the SEER/IARC incidence-registry pipelines; it aggregates RCT and cohort evidence on screening effectiveness. Treated as an independent source here for the screening and overdiagnosis claims.
-
[5] Siegel RL, Giaquinto AN, Jemal A / CA: A Cancer Journal for Clinicians — Cancer statistics, 2024
Cancer statistics, 2024- Statistic
Prostate cancer mortality rates are approximately two-fold higher in Black men than in White men in the US, alongside stomach and uterine corpus cancers- Excerpt
“"Compared to White people, mortality rates are two-fold higher for prostate, stomach and uterine corpus cancers in Black people." ”
- Source data from
- 2024-01-17
- Accessed
- 2026-04-11 · archived copy
- Calculation
- Siegel et al. 2024 is the authoritative annual ACS peer-reviewed cancer statistics summary. The ~2x Black-vs-White prostate cancer mortality ratio is the canonical figure used for the African American row in the regional_breakdown block and the "African ancestry" row in personal_factor_multipliers. The gap reflects both biology (higher incidence and more aggressive disease at diagnosis in men of African descent) and differential access to timely treatment; the paper does not attempt to decompose the two contributions precisely. The overall prostate cancer death rate has been declining ~0.6% per year (per SEER), so the absolute gap is narrowing even as the ratio persists.
- Independence
- Uses SEER incidence data and NCHS mortality data — same upstream as the SEER Stat Facts source above. Treated as a dependent but methodologically richer peer-reviewed analysis of the same pipeline.